Clinical Trials | July 01, 2025
Moderna announces promising efficacy results from mRNA flu vaccine trial
mRNA-1010 demonstrated superior relative vaccine efficacy
mRNA-1010 demonstrated superior relative vaccine efficacy
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
For the full year FY25, net profit soared 12x to Rs 345 crore
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Subscribe To Our Newsletter & Stay Updated
